Page last updated: 2024-11-04

meglumine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Meglumine, also known as N-methylglucamine, is a synthetic amino sugar derivative of glucose. It is a white, crystalline solid that is soluble in water. Meglumine is used as a pharmaceutical excipient, primarily in the formulation of injectable drugs. It is also used as a contrast agent in medical imaging. Meglumine acts as a solubilizer and buffer, improving the stability and solubility of drugs in solution. It is often used in combination with other pharmaceutical excipients, such as sodium chloride and water. Meglumine is well-tolerated by patients, and its safety profile has been well-established. Its importance in pharmaceuticals lies in its ability to enhance the bioavailability and stability of drugs, leading to improved therapeutic outcomes. Meglumine is studied extensively to understand its interactions with various drug molecules and to optimize its use in drug formulation.'

Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8567
CHEMBL ID1200570
CHEBI ID59732
SCHEMBL ID2193
MeSH IDM0013297
PubMed CID4049
CHEMBL ID333195
CHEBI ID95217
SCHEMBL ID5584
MeSH IDM0013297

Synonyms (145)

Synonym
BIDD:GT0676
AC-4692
AB00430469-03
n-methylglucamine
n-methyl-d-glucamine
d-glucitol, 1-deoxy-1-(methylamino)-
meglumin
6284-40-8
nsc-7391
1-deoxy-1-methylaminosorbitol
nsc-52907
1-deoxy-1-(methylamino)-d-glucitol
1-methylamino-1-deoxy-d-glucitol
(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
meglumine
meglumine, meets usp testing specifications
n-methyl-d-glucamine, 99.0-100.5% (titration)
NCGC00166125-01
meglumine (jp17/usp/inn)
D01796
megluminum [inn-latin]
sorbitol, 1-deoxy-1-methylamino-
n-methylsorbitylamine
meglumina [inn-spanish]
einecs 228-506-9
HMS2089B05
megluminum
CHEBI:59732 ,
meglumina
CHEMBL1200570
d(-)-n-methylglucamine
AKOS005167162
M0227
A834035
(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol
NCGC00255365-01
tox21_302037
dtxcid503244
dtxsid0023244 ,
tox21_112330
nsc-759607
nsc759607
pharmakon1600-01300029
c7h17no5
ec 228-506-9
6hg8ub2muy ,
meglumine [usp:inn:ban:jan]
unii-6hg8ub2muy
AM20100540
S1974
AKOS015850890
BRD-K28595280-001-01-1
meglumine [usp-rs]
n-methylglucamine [mi]
meglumine [who-dd]
meglumine [ep monograph]
meglumine [usp monograph]
meglumine [ii]
megluminum [who-ip latin]
meglumine [vandf]
methylglucamine [inci]
meglumine [inn]
meglumine [who-ip]
meglumine [jan]
meglumine [mart.]
meglumine [orange book]
CCG-220884
HY-B0342
SCHEMBL2193
tox21_112330_1
NCGC00166125-02
n-methyl glucamine
n-methyl-1-amino-1-deoxy-d-glucitol
(2r,3r,4r,5s)-6-methylamino-hexane-1,2,3,4,5-pentaol
n-methyl-glucamine
1-deoxy-1-(methylamino)-glucitol
n-methyl-(2 (s),3 (r),4 (r),5 (r),6-pentahydroxy-hexyl)-amine
AC-17087
AB00430469_05
n-methyl-d-glucamine, reagentplus(r), >=99.0% (t)
mfcd00004707
meglumine, united states pharmacopeia (usp) reference standard
sr-05000001446
SR-05000001446-1
n-methyl-d-glucamine, european pharmacopoeia (ep) reference standard
meglumine, pharmaceutical secondary standard; certified reference material
n-methyl-d-glucamine, vetec(tm) reagent grade, 99%
SBI-0206683.P002
HMS3714B10
SW199350-2
Q288875
AS-12002
meglumine 100 microg/ml in acetonitrile
EN300-2394659
Z1255485274
methylglucamine
nsc7391
d-(-)-n-methylglucamine
methylglucamin
nsc52907
BSPBIO_000668
NCGC00179482-01
BPBIO1_000736
PRESTWICK3_000884
AB00513945
smr000387082
MLS001048885
n-methyl-d-glucamine, 99%
n-methyl-d(-)-glucamine
nsc 7391
nsc 52907
glucitol, 1-deoxy-1-(methylamino)-, d-
PRESTWICK1_000884
PRESTWICK0_000884
SPBIO_002887
PRESTWICK2_000884
CHEMBL333195
AKOS005068279
FT-0655868
HMS1570B10
6-(methylamino)hexane-1,2,3,4,5-pentol
1-deoxy-1-(methylamino)hexitol
STK801441
HMS2097B10
BBL007602
HMS2267B12
FT-0607695
AB00513945-08
MLS006011915
SCHEMBL5584
6-methylaminohexane-1,2,3,4,5-pentaol
Q-201347
1-deoxy-1-(methylamino)hexitol #
SR-01000758225-2
sr-01000758225
CHEBI:95217
HMS3655B07
(2r,3r,4r,5s)-6-methylaminohexane-1,2,3,4,5-pentol
n-methylglycamine
Q27167037
VS-01687
90191-92-7
EN300-152603
meglumine n-methyl-d-glucamine
DTXSID70859264

Research Excerpts

Toxicity

Gadopentetate dimeglumine appears to be safe in doses up to 21 mmol/m2 in conjunction with barrier disruption in rats. While it is unlikely that these toxic effects would be seen at the doses used for clinical imaging by the intravenous route.

ExcerptReferenceRelevance
"The adverse effects following lumbar myelography and ventriculography with meglumine iothalamate (Conray Meglumin), meglumine iocarmate (Dimer-X, Bis-Conray) and metrizamide (Amipaque), and after thoracic and cervical myelography and cisternography with metrizamide are reviewed."( Adverse effects of water-soluble contrast media in myelography, cisternography and ventriculography. A review with special reference to metrizamide.
Skalpe, IO, 1977
)
0.26
" To determine its safety, the authors summarized data concerning adverse reactions, laboratory parameters, and other assessments for 1,068 adult patients who received gadopentetate dimeglumine in United States clinical trials."( Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.
Blumenfield, DM; Blumetti, RF; Goldstein, HA; Holyoak, WL; Hugo, FP; Kashanian, FK, 1990
)
0.28
"To quantify the rate of adverse reactions to gadopentetate dimeglumine."( Clinical safety of gadopentetate dimeglumine.
Gifford, LM; Gross, CA; Lasser, TA; Lauber-Huber, C; Nelson, KL, 1995
)
0.29
" Two serious adverse reactions occurred and were attributed to underlying disease."( Clinical safety of gadopentetate dimeglumine.
Gifford, LM; Gross, CA; Lasser, TA; Lauber-Huber, C; Nelson, KL, 1995
)
0.29
"Gd-DTPA is a well-characterized, safe contrast agent frequently used in magnetic resonance imaging (MRI) of the central nervous system."( Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
Kuijpers, TJ; Oudkerk, M; Sijens, PE; Van Beek, EJ, 1995
)
0.29
" Patients were questioned 1 hour after injection, and adverse reactions were recorded."( Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
Kuijpers, TJ; Oudkerk, M; Sijens, PE; Van Beek, EJ, 1995
)
0.29
"This double-blind, randomized, clinical trial comparing Gd-DTPA and Gd-DOTA revealed no serious adverse reactions, whereas minor adverse reactions were encountered in fewer than 1% of patients."( Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
Kuijpers, TJ; Oudkerk, M; Sijens, PE; Van Beek, EJ, 1995
)
0.29
" No adverse clinical events or clinically important trends in vital signs were observed after contrast administration."( Gadopentetate dimeglumine-enhanced MR of the brain: clinical utility and safety in patients younger than two years of age.
Brunberg, JA; Eldevik, OP, 1994
)
0.29
"Gadopentetate dimeglumine appears to be safe in doses up to 21 mmol/m2 in conjunction with barrier disruption in rats."( Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: toxicity and MR findings.
Barnett, PA; Mass, M; McCormick, CI; Neuwelt, EA; Ramsey, FL; Roman-Goldstein, SM; Shannon, EM; Szumowski, J,
)
0.13
" While it is unlikely that these toxic effects would be seen at the doses used for clinical imaging by the intravenous route, gadopentetate dimeglumine clearly has some neurotoxic and neuropathologic potential."( Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats.
Cavanagh, JB; Nolan, CC; Ray, DE; Williams, SC, 1996
)
0.29
" Adverse events were reported in 13 (4%) patients given gadodiamide injection and 8 (6%) given gadopentetate dimeglumine; few patients reported injection-associated discomfort."( MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications.
Gordon, P; Hugo, F; Lundby, B, 1996
)
0.29
" Finally, the results shows that the treatment with pentavalent antimony in doses of 40 mg Sb/kg/day was less tolerated on account of its renal toxic effects."( [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
de Paula, CD; Furtado, Rde S; Leal, PP; Rodrigues, ME; Rosa, TT; Sampaio, JH; Sampaio, RN; Veiga, JP,
)
0.13
" We describe a fatal adverse event secondary to use of the high osmolality agent iothalmate meglumine 30%."( Fatal adverse event secondary to high osmolality contrast agent.
Guharoy, R; Lehmann, D; Medicis, J, 1998
)
0.3
"Gadobenate dimeglumine was safe and well tolerated in healthy volunteers and patients, with pharmacokinetics described adequately as a distribution phase and an elimination phase."( Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.
Kirchin, M; Lorusso, V; Pirovano, G; Spinazzi, A, 1999
)
0.3
"Gadobenate dimeglumine is a safe and efficacious MR imaging contrast agent suitable for both delayed and dynamic imaging of the liver."( Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.
Kirchin, M; Lorusso, V; Pirovano, G; Spinazzi, A, 1999
)
0.3
" No Gd(3+)-related adverse events occurred."( Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.
Bensel, K; Davies, BE; LaFrance, ND; Lambrecht, LJ; McCloud, S; Parker, JR; Swan, SK; Townsend, R, 1999
)
0.3
" Adverse effects were observed in 14 (56%) VL episodes."( High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Corzo, JE; de la Rosa, R; Delgado, J; González-Moreno, MP; Leal, M; Lissen, E; Macías, J; Pineda, JA; Sánchez-Quijano, A, 1999
)
0.3
"Based on the wide margins of safety demonstrated in different species, particularly in primates, gadobenate dimeglumine can be considered as safe in the range of clinical doses recommended for magnetic resonance imaging."( Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium.
Bussi, S; de Haën, C; Morisetti, A; Tirone, P, 1999
)
0.3
" Therefore, these changes were not toxic changes."( [General toxicity study of gadobenate dimeglumine formulation (E7155) (3)--4-week repeated dose intravenous toxicity study followed by 4-week recovery period in rats].
Aoki, T; Bussi, S; Masters, RE; Morisetti, A; Sagami, F; Tirone, P, 1999
)
0.3
" There were no toxic clinical signs of treatment."( [Reproductive and developmental toxicity study of gadobenate dimeglumine formulation (E7155) (2)--Combined study of effects on fertility and embryo-fetal toxicity in female rats by intravenous administration].
Baguley, JK; Bussi, S; Kawaguchi, T; Morisetti, A; Sagami, F; Tirone, P, 1999
)
0.3
" The cumulative doses of gadobenate dimeglumine were well tolerated and as safe as gadodiamide."( A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Armstrong, MR; Barr, RG; Berger, BL; Czervionke, LF; Gonzalez, CF; Halford, HH; Kanal, E; Kuhn, MJ; Levin, JM; Low, RN; Runge, VM; Tanenbaum, LN; Wang, AM; Wong, W; Yuh, WT; Zoarski, GH, 2001
)
0.31
" For adult patient volunteers, the overall incidence of adverse events (AEs) was 19."( Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.
Kirchin, MA; Pirovano, G; Spinazzi, A; Venetianer, C, 2001
)
0.31
" The contrast agent was well tolerated and safe with an overall incidence of adverse events comparable to that of placebo."( Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.
Bensel, K; Davies, A; Davies, BE; Kirchin, MA; Lafrance, ND; Lorusso, V; Parker, JR, 2002
)
0.31
"9% and no serious adverse side effects."( Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey.
Allahverdiyev, AM; Culha, G; Durdu, M; Memisoglu, HR; Uzun, S, 2004
)
0.32
"Glucantime is the most common stibied derivative used to treat cutaneous leishmaniasis (CL) in Tunisia; however adverse effects have been reported."( [Glucantime injection: benefit versus toxicity].
Bouassida, S; Boudaya, S; Maalej, N; Masmoudi, A; Mseddi, M; Souissi, A; Turki, H; Zahaf, A, 2005
)
0.33
"This retrospective study deals with the various adverse of intramuscular glucantime used for CL."( [Glucantime injection: benefit versus toxicity].
Bouassida, S; Boudaya, S; Maalej, N; Masmoudi, A; Mseddi, M; Souissi, A; Turki, H; Zahaf, A, 2005
)
0.33
"Nineteen patients (21%) receiving intramuscular Glucantime developed adverse effects."( [Glucantime injection: benefit versus toxicity].
Bouassida, S; Boudaya, S; Maalej, N; Masmoudi, A; Mseddi, M; Souissi, A; Turki, H; Zahaf, A, 2005
)
0.33
" No adverse effect of MA on the mothers was noted at any dose level."( Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat.
De-Carvalho, RR; Miekeley, N; Miranda, ES; Paumgartten, FJ, 2006
)
0.33
"Commercialized gadoterate meglumine diluted with 94% ethanol was not shown to have released toxic Gd3+ during storage times that exceed its physiologic circulation and excretion times after intravenous injection by a factor of more than 100."( Contrast material-enhanced visualization of the ablation medium for magnetic resonance-monitored ethanol injection therapy: imaging and safety aspects.
Andreisek, G; Ess, S; Fröhlich, JM; Nanz, D; Pfammatter, T; Treiber, K; Weishaupt, D, 2006
)
0.33
" It has been proposed that the more active and toxic trivalent antimony form Sb(III) plays a critical role in their antileishmanial activity and toxicity."( Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
de Oliveira, FB; Demicheli, C; Dzamitika, SA; Falcão, CA; Frézard, F; Garnier-Suillerot, A; Marbeuf, C; Rossi-Bergmann, B, 2006
)
0.33
" The aim of this retrospective study was to determine the adverse effects of intralesional Glucantime and to calculate the risk/benefit rate of this treatment."( [Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].
Boudaya, S; Maalej, N; Masmoudi, A; Turki, H; Zahaf, A, 2006
)
0.33
"The adverse effects of intralesional Glucantime are mostly infections, mainly observed in cephalic localization, and stibio-intolerance."( [Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].
Boudaya, S; Maalej, N; Masmoudi, A; Turki, H; Zahaf, A, 2006
)
0.33
"In total, 413 of 2982 (14%) adult subjects receiving MultiHance reported at least one adverse event (AE) definitely or potentially related to MultiHance, an incidence that was similar to that observed with placebo (21/127, 17%) or active controls (59/723, 8%)."( Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Parker, JR; Pirovano, G; Shellock, FG; Spinazzi, A; Venetianer, C, 2006
)
0.33
" A questionnaire recording adverse effects was completed by a physician in each treatment centre."( Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
Bermúdez, H; Boelaert, M; Chappuis, F; Desjeux, P; Dujardin, JC; Garcia, L; Rojas, E, 2006
)
0.33
"To test in vitro whether gadolinium-based contrast agents induce fewer toxic effects on renal tubular cells than does an iodinated contrast medium at concentrations used for angiography."( Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.
Grgic, A; Heckmann, MB; Heinrich, MC; Kohlbacher, S; Kuhlmann, MK; Scheer, M; Uder, M, 2007
)
0.34
"0 T is safe in the acute and chronic phase after MI treated with primary stenting."( 3.0 T cardiovascular magnetic resonance in patients treated with coronary stenting for myocardial infarction: evaluation of short term safety and image quality.
Beek, AM; Hirsch, A; Hofman, MB; Nijveldt, R; Piek, JJ; Spijkerboer, AM; van Rossum, AC, 2008
)
0.35
" It may create severe adverse effects."( [Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report].
Ameur, HB; Amor, SB; Becher, SB; Fitouri, Z; Matoussi, N, 2007
)
0.34
" Adverse effects were recorded passively in all the subjects, and actively, using a standardized questionnaire, in a sub-group of the patients given AmB."( Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda.
Cavailler, P; Chappuis, F; Couffignal, S; Loutan, L; Mueller, Y; Nguimfack, A; Rwakimari, JB, 2008
)
0.35
" This new delivery system could offer a new pharmacological tool for the treatment of leishmaniosis that reduces the doses required, lowering toxic side effects because of meglumine antimoniate."( In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum.
Carrió, J; García, E; Miñarro, M; Pérez, P; Portus, M; Pujals, G; Suñé-Negre, JM; Tico, JR, 2008
)
0.35
" Adverse effects related to systemic administration of Glucantime are frequent."( [Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia].
Badri, T; Ben Brahim, M; Ben Jannet, S; Chouk, S; Daghfous, R; El Aïdli, S; Fenniche, S; Marrrak, H; Mlika, BR; Mokhtar, I, 2008
)
0.35
"2%) presented product-related adverse events concerning the gastrointestinal tract."( Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C, 2009
)
0.35
"Retrospective analysis of the occurrence of adverse events and the diagnostic efficacy of a paramagnetic contrast agent with weak intermittent protein binding and high relaxivity."( [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Goyen, M; Herborn, CU; Jäger-Booth, I; Lodemann, KP; Spinazzi, A, 2009
)
0.35
"MultiHance is a safe and very well tolerated contrast agent for magnetic resonance imaging (MRI) with a profile and frequency of adverse events similar to other extracellular MR contrast materials."( [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Goyen, M; Herborn, CU; Jäger-Booth, I; Lodemann, KP; Spinazzi, A, 2009
)
0.35
" These findings indicate that Glucantime is a promutagenic compound that causes damage to DNA after reduction of pentavalent antimony (SbV) into the more toxic trivalent antimony (SbIII) in the antimonial drug meglumine antimoniate."( Genotoxic effects of the antileishmanial drug Glucantime.
Alves, EV; Arruda, VO; de Azevedo, AP; Lima, MI; Monteiro, SG; Pereira, SR, 2010
)
0.36
" During treatment, patients underwent periodic blood exams and were interviewed weekly about the incidence of adverse symptoms."( Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
Caldas, ED; Neves, DB; Sampaio, RN, 2009
)
0.35
" The main adverse symptoms were arthralgia and myalgia; laboratory results showed mainly lymphocytosis and eosinophilia."( Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
Caldas, ED; Neves, DB; Sampaio, RN, 2009
)
0.35
"We found some significant correlations between antimony concentrations, adverse symptoms and laboratory alterations, strengthening the hypothesis of a dose-dependent relationship between antimony concentration in plasma and skin and side effects."( Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
Caldas, ED; Neves, DB; Sampaio, RN, 2009
)
0.35
" The safety of miltefosine-allopurinol combination therapy was confirmed by lack of effect on renal and hepatic parameters and adverse reactions."( Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C, 2009
)
0.35
" The vaccine was safe and well tolerated."( A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Alves, FP; Ashman, JA; Beckmann, AM; Bogatzki, LY; Campos-Neto, A; Coler, RN; Cowgill, KD; Fernandes, DF; Kahn, SJ; Nascimento, E; Piazza, FM; Pine, SO; Reed, SG; Vieira, EP, 2010
)
0.36
" Thirty-three non-serious and six serious adverse events (two pancreatitis, one renal failure and three deaths) were observed in 26 patients."( Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
Balasegaram, M; Hailu, A; Hailu, W; Hurissa, Z; Omollo, R; Tafes, H; Weldegebreal, T; Yifru, S, 2010
)
0.36
" If precautions could be taken before the repeated administration of gadolinium-based contrast media, then the awareness and management of adverse reactions would be more efficient."( Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi, T; Takahashi, S, 2010
)
0.36
"To assess the safety and efficacy of gadoterate meglumine (Gd-DOTA) [Magnescope® in Japan, Dotarem® in other countries], a gadolinium-based contrast agent, in patients undergoing imaging of the brain/spinal cord and/or trunk/limbs, and to identify factors associated with the onset of adverse reactions."( Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi, T; Takahashi, S, 2010
)
0.36
" After Gd-DOTA administration, 13 patient baseline characteristics were used to explore factors that might predict a greater likelihood of acute non-renal adverse reactions."( Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi, T; Takahashi, S, 2010
)
0.36
" The low incidence of adverse reactions (<1%) and the absence of serious adverse reactions reported during the survey period showed that Gd-DOTA was very well tolerated."( Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi, T; Takahashi, S, 2010
)
0.36
" A prudent approach would be to (1) identify patients at high risk to develop contrast-related complications, (2) use noncontrast-based imaging techniques in these patients, as long as they are suitably diagnostic and safe and (3) if the risk:benefit ratio of the imaging information favors a contrast-based study, then appropriate prophylactic steps and use of contrast agents with the lowest risk of complication should be used after obtaining informed consent."( Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella, MA; Reilly, RF, 2011
)
0.37
" Their administration to experimental animals for 30 days did not cause toxic effects on the functional and morphological state of main systems and organs."( [Preclinical study of Reamberin and Remaxol safety].
Dagaev, SG; Kovalenko, AL; Lesiovskaia, EE; Petrov, AIu; Savateev, AV; Savateeva-Liubimova, TN; Shevchuk, MK; Sivak, KV; Stosman, KI; Sukhanov, DS, 2010
)
0.36
" No severe adverse events occurred."( Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak Talhari, C; Chrusciak-Talhari, A; da Silva, RM; de Oliveira Penna, G; Dietze, R; Gadelha Yamashita, EP; Lima Machado, PR; Talhari, S, 2011
)
0.37
"Among the problems associated to leishmaniasis, the two most outstanding ones are the lack of a vaccine and the adverse effects caused by drugs use for its control."( An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations.
Delgado, G; Granados, D; Mariño, A; Plaza, D; Sánchez, Y, 2011
)
0.37
"To determine whether electronic injection of gadolinium-based contrast media through a range of small-caliber, single-lumen PICCs would be safe without risk of catheter rupture over the range of clinical protocols and determine whether programmed flow rates and volumes were realized when using PICCs for contrast delivery."( Injection of gadolinium contrast through pediatric central venous catheters: a safety study.
Ennis, DB; Finn, JP; Kung, GL; Moghaddam, AN; Moriarty, JM; Ramos, Y, 2012
)
0.38
"The purpose was to objectively evaluate a recently FDA-approved gadolinium-based contrast agent (GBCA) in comparison to our standard GBCA for acute adverse events and image quality by blinded evaluation."( Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Castillo, M; Hernandes, Mde A; Semelka, RC; Stallings, CG, 2013
)
0.39
" Assessment was made of acute adverse events focusing on objective observations of vomiting, hives, and moderate and severe reactions."( Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Castillo, M; Hernandes, Mde A; Semelka, RC; Stallings, CG, 2013
)
0.39
"No patient experienced acute adverse events with either agent."( Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Castillo, M; Hernandes, Mde A; Semelka, RC; Stallings, CG, 2013
)
0.39
" This proof-of-concept study showed that both GBCAs evaluated exhibited consistent good image quality and no noteworthy adverse events."( Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.
Castillo, M; Hernandes, Mde A; Semelka, RC; Stallings, CG, 2013
)
0.39
" This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®) ) and its influence on clinical laboratory parameters."( Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Esfandiarpour, I; Farajzadeh, S; Fathabadi, EA; Heshmatkhah, A; Rahnama, Z, 2012
)
0.38
"The occurrence of severe adverse reactions, particularly of anaphylactic shock, should be considered before treatment with Glucantime(®) is initiated."( Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Esfandiarpour, I; Farajzadeh, S; Fathabadi, EA; Heshmatkhah, A; Rahnama, Z, 2012
)
0.38
"Gadolinium-based MR contrast agents have long been considered safe for routine diagnostic imaging."( Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
Bücker, A; Fries, P; Kirchin, MA; Schneider, G; Schürholz, H, 2013
)
0.39
" Monitoring for adverse events was performed for at least 24 h after each gadobenate dimeglumine injection."( Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
Bücker, A; Fries, P; Kirchin, MA; Schneider, G; Schürholz, H, 2013
)
0.39
"No clinically adverse events were reported among children who had one MRI scan only or among children who had several examinations."( Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
Bücker, A; Fries, P; Kirchin, MA; Schneider, G; Schürholz, H, 2013
)
0.39
"No adverse events were recorded during the first 24 h following administration of gadobenate dimeglumine in 200 children."( Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
Bücker, A; Fries, P; Kirchin, MA; Schneider, G; Schürholz, H, 2013
)
0.39
" We found that MMWC was toxic for two parasite forms."( In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
Barbosa, H; Delgado, G; Gutiérrez, J; Pinzón, J; Vallejo, B, 2013
)
0.39
"In recent decades, numerous methods have been developed for data mining of large drug safety databases, such as Food and Drug Administration's (FDA's) Adverse Event Reporting System, where data matrices are formed by drugs such as columns and adverse events as rows."( Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection.
Huang, L; Tiwari, R; Zalkikar, J; Zheng, D, 2017
)
0.46
"Nineteen patients tolerated the treatment well, with no major adverse events."( Safety and efficacy of sonographically guided high-intensity focused ultrasound for symptomatic uterine fibroids: preliminary study of a modified protocol.
Ahuja, AT; Cheung, EC; Ho, SS; Leung, JH; Leung, VY; Tong, MM; Wong, AS; Yu, SC, 2014
)
0.4
"Sonographically guided high-intensity focused ultrasound using a modified protocol may be safe and effective for symptomatic uterine fibroids in selected patients to avoid skin burns."( Safety and efficacy of sonographically guided high-intensity focused ultrasound for symptomatic uterine fibroids: preliminary study of a modified protocol.
Ahuja, AT; Cheung, EC; Ho, SS; Leung, JH; Leung, VY; Tong, MM; Wong, AS; Yu, SC, 2014
)
0.4
" Adverse events (AEs) were prospectively recorded."( Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Dohan, A; Gottschalk, A; Patkar, D; Soyer, P, 2017
)
0.46
"09% of all patients) were considered related to gadoterate meglumine and classified as adverse drug reaction (ADR)."( Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Dohan, A; Gottschalk, A; Patkar, D; Soyer, P, 2017
)
0.46
" Adverse drug reactions occurred in 5 of 1537 patients (0."( Diagnostic efficacy and safety of gadoteric acid MR mammography in 1537 patients.
Auer, J; Braun, J; de Bucourt, M; Hamm, B; Heine, O; Pociej, J; Seithe, T; Vahldiek, J; Wolf, M; Wolny, D, 2016
)
0.43
"This noninterventional surveillance study shows IV gadoteric acid to be a safe and effective contrast agent for use in MR mammography."( Diagnostic efficacy and safety of gadoteric acid MR mammography in 1537 patients.
Auer, J; Braun, J; de Bucourt, M; Hamm, B; Heine, O; Pociej, J; Seithe, T; Vahldiek, J; Wolf, M; Wolny, D, 2016
)
0.43
"Currently, the treatment of leishmaniasis is increasingly insufficient as current antileishmanial drugs have many disadvantages such as toxic side effects, high cost, and growing drug resistance."( Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor, ES; Allahverdiyev, AM; Bagirova, M; Rafailovich, M, 2017
)
0.46
" Few studies showing conflictive data about their efficacy and adverse events in pediatric population are available."( Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges, MM; Carranza-Tamayo, CO; Noronha, EF; Pranchevicius, MC; Romero, GA,
)
0.13
" All patients reported adverse events (AE)."( Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges, MM; Carranza-Tamayo, CO; Noronha, EF; Pranchevicius, MC; Romero, GA,
)
0.13
"N-methylglucamine antimoniate and amphotericin B deoxycholate have similar efficacy and adverse events rate in pediatric patients with VL."( Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges, MM; Carranza-Tamayo, CO; Noronha, EF; Pranchevicius, MC; Romero, GA,
)
0.13
" In the 3 decades since initial approval, these have proven in general to be very safe for human administration."( Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommend
Runge, VM, 2017
)
0.46
" Twenty-six adverse events occurred postinjection in 13 subjects (28."( A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
Bourrinet, P; de Buttet, S; Felices, M; Jurkiewicz, E; Koob, M; Scala, M, 2018
)
0.48
" A total of 29 cases of adverse reactions were observed in the experiment."( [Post-marketing study on clinical safety of ginkgo diterpene lactone meglumine injection in 6 300 patients with ischemic stroke].
Gao, Y; Lai, XX; Tan, ZH; Wang, Y; Xu, TS; Yu, M; Zhao, JJ; Zhou, L, 2017
)
0.46
" Safety data were assessed for adverse events and, when available, vital signs and electrocardiogram and clinical laboratory values obtained from 48 hours before until 48 hours after the MR imaging examination."( Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.
Colosimo, C; Enterline, DS; Martin, KW; Parmar, HA; Triulzi, FM, 2019
)
0.51
"Gadobenate dimeglumine is safe and effective for pediatric MR imaging."( Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.
Colosimo, C; Enterline, DS; Martin, KW; Parmar, HA; Triulzi, FM, 2019
)
0.51
" In order to detect and enumerate even rare adverse events (AE) and serious adverse events (SAE), and to relate them with patients' baseline characteristics and diagnostic effectiveness, high quantity sample size is necessary."( Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
Auer, J; Braun, J; Busse, R; Darmon-Kern, E; de Bucourt, M; Hamm, B; Heine, O; Maurer, M; Meyl, T, 2020
)
0.56
"Gadoteric acid is a safe peri-examinational and effective contrast agent for MRI in routine practice."( Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
Auer, J; Braun, J; Busse, R; Darmon-Kern, E; de Bucourt, M; Hamm, B; Heine, O; Maurer, M; Meyl, T, 2020
)
0.56
"To assess the safety of gadoterate meglumine (Dotarem) in patients younger than 2 years of age by evaluating adverse events following contrast administration."( Safety of gadoterate meglumine in children younger than 2 years of age.
Farmakis, SG; Hardy, AK; Mahmoud, SY; Tao, TY; Wilson-Flewelling, SA, 2020
)
0.56
" The occurrence of adverse events was assessed at the time of injection, 2 h after MRI, and by phone contact using a standard questionnaire 24 h after MRI."( Safety of gadoterate meglumine in children younger than 2 years of age.
Farmakis, SG; Hardy, AK; Mahmoud, SY; Tao, TY; Wilson-Flewelling, SA, 2020
)
0.56
" Thirty-four adverse events were reported in 23 patients overall (15."( Safety of gadoterate meglumine in children younger than 2 years of age.
Farmakis, SG; Hardy, AK; Mahmoud, SY; Tao, TY; Wilson-Flewelling, SA, 2020
)
0.56
"No patient experienced adverse events directly related to gadoterate meglumine."( Safety of gadoterate meglumine in children younger than 2 years of age.
Farmakis, SG; Hardy, AK; Mahmoud, SY; Tao, TY; Wilson-Flewelling, SA, 2020
)
0.56
"Between 2008 and 2018, consecutive patients with HFrEF defined by left ventricular ejection fraction <40% prospectively referred for vasodilator stress perfusion CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined by cardiovascular death or nonfatal myocardial infarction."( Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction.
Bonnet, G; Champagne, S; Claude Morice, M; Garot, J; Garot, P; Hovasse, T; Kinnel, M; Landon, V; Louvard, Y; Pezel, T; Sanguineti, F; Unterseeh, T, 2020
)
0.56
" Stress CMR was well tolerated without any adverse events."( Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction.
Bonnet, G; Champagne, S; Claude Morice, M; Garot, J; Garot, P; Hovasse, T; Kinnel, M; Landon, V; Louvard, Y; Pezel, T; Sanguineti, F; Unterseeh, T, 2020
)
0.56
"Stress CMR is safe and has a good discriminative prognostic value to predict the occurrence of MACE in patients with HFrEF."( Safety and Prognostic Value of Vasodilator Stress Cardiovascular Magnetic Resonance in Patients With Heart Failure and Reduced Ejection Fraction.
Bonnet, G; Champagne, S; Claude Morice, M; Garot, J; Garot, P; Hovasse, T; Kinnel, M; Landon, V; Louvard, Y; Pezel, T; Sanguineti, F; Unterseeh, T, 2020
)
0.56
" However, treatment interruptions due to adverse events (AEs) and non-adherence are frequent."( A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis.
Barroso, DH; Ferreira, MF; Gomes, CM; Martins, SS; Motta, JOCD; Paula, CDR; Porto, C; Rodrigues, BC; Sampaio, RNR, 2020
)
0.56
" Safety data were collected by spontaneous patient adverse event (AE) reporting."( Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.
Alcázar, A; Fraga, P; Jakobsen, JÅ; Müller, FHH; Outteryck, O; Panebianco, V; Pietura, R; Quattrocchi, CC; Reith, W; Sampedro, A, 2021
)
0.62
" The presence of vesicles at the site of heat application was the most common adverse event reported associated with the use of TT; while vomiting (31."( A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World.
Alvarez, F; Arana, B; Boni, M; Echevarria, J; Jiménez, A; Llanos-Cuentas, A; López, L; Méndez, C; Quintero, J; Ramos, AP; Rode, J; Tabares, Y; Valencia, B; Vélez, I, 2022
)
0.72
"Symptoms associated with gadolinium exposure were identified from a review of the scientific literature, and the corresponding preferred terms were searched in each system organ class (SOC) category recorded in the European and North American pharmacovigilance databases EudraVigilance (EV) and FDA Adverse Event Reporting System (FAERS), respectively."( Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure.
Joseph, A; Lancelot, E; Shahid, I, 2022
)
0.72
" Though the risk of contrast administration can never be entirely ignored, especially in patients with low eGFR, our study indicates that safe administration of GM can be performed even in patients with severe kidney disease."( Safety profile of Gadoterate meglumine on the renal function of patients with severe kidney disease.
Adams, W; El-Bulbul, J; Goldberg, A; Jawahar, A; Joyce, C; Yacoub, J, 2022
)
0.72
"4% alone or in combination with national standard treatment is safe with high-efficacy rate and warrants further investigation during phase 3 clinical trials."( Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
Afshari, F; Eskandari, S; Firooz, A; Jaafari, M; Javadi, A; Khamesipour, A; Mohammadi, A; Mortazavi, H; Tasbihi, M, 2022
)
0.72

Pharmacokinetics

The safety and pharmacokinetic profile of gadobenate dimeglumine, a gadolinium (Gd3+) chelate complex in development as a contrast agent for MRI, were evaluated in a placebo-controlled, double-blind, multicenter trial.

ExcerptReferenceRelevance
"The pharmacokinetic profile of antimony in dogs was defined by administering it intravenously, intramuscularly and subcutaneously as N-methylglucamine antimoniate at a dose of about 25."( Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog.
Belloli, C; Carli, S; Ceci, L; De Natale, G; Madonna, M; Marcotrigiano, GO; Ormas, P; Tassi, P, 1994
)
0.29
"Dynamic MR image series were analyzed with a pharmacokinetic two-compartment model."( Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; van Kaick, G; Zuna, I, 1996
)
0.29
" The signal-time curves for the suspected lesions were analyzed within the framework of a pharmacokinetic two-compartment model and displayed as color-coded images."( Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; van Kaick, G; Zuna, I, 1996
)
0.29
"Analysis of the pharmacokinetic mapping data showed significantly shorter (p < ."( Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; van Kaick, G; Zuna, I, 1996
)
0.29
"Analysis of color-coded pharmacokinetic maps is more effective than conventional MR imaging in distinguishing between malignant and benign conditions in patients who have pelvic lesions after treatment of cervical carcinoma."( Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; van Kaick, G; Zuna, I, 1996
)
0.29
"To stage advanced cervical carcinoma with conventional or pharmacokinetic magnetic resonance (MR) imaging by correlating imaging findings with whole-mount specimens and histopathologic findings."( Cervical carcinoma: comparison of standard and pharmacokinetic MR imaging.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; Schönberg, S; van Kaick, G; Weikel, W; Zuna, I, 1996
)
0.29
" Signal intensity changes versus time were analyzed by using a pharmacokinetic model and parameter values displayed as a color-coded overlay."( Cervical carcinoma: comparison of standard and pharmacokinetic MR imaging.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; Schönberg, S; van Kaick, G; Weikel, W; Zuna, I, 1996
)
0.29
" The overall accuracy for tumor staging was 73% for T2-weighted, 81% for T1-weighted, and 92% for pharmacokinetic MR imaging."( Cervical carcinoma: comparison of standard and pharmacokinetic MR imaging.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; Schönberg, S; van Kaick, G; Weikel, W; Zuna, I, 1996
)
0.29
"T2-weighted turbo SE images are still superior to contract medium-enhanced T1-weighted SE or pharmacokinetic MR images in the diagnosis of parametrial infiltration by uterine cervical carcinoma."( Cervical carcinoma: comparison of standard and pharmacokinetic MR imaging.
Brix, G; Essig, M; Hawighorst, H; Hoffmann, U; Knapstein, PG; Knopp, MV; Schaeffer, U; Schönberg, S; van Kaick, G; Weikel, W; Zuna, I, 1996
)
0.29
"The safety and pharmacokinetic profile of gadobenate dimeglumine, a gadolinium (Gd3+) chelate complex in development as a contrast agent for MRI, were evaluated in a placebo-controlled, double-blind, multicenter trial."( Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.
Bensel, K; Davies, BE; LaFrance, ND; Lambrecht, LJ; McCloud, S; Parker, JR; Swan, SK; Townsend, R, 1999
)
0.3
"Evaluation of the pharmacokinetic behavior of gadobenate dimeglumine, a new multipurpose parenteral contrast agent for magnetic resonance imaging."( Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance).
Arbughi, T; de Haën, C; Lorusso, V; Tirone, P, 1999
)
0.3
" A compartmental pharmacokinetic model was developed to describe dynamic signal intensity-time curves."( Gd-BOPTA transport into rat hepatocytes: pharmacokinetic analysis of dynamic magnetic resonance images using a hollow-fiber bioreactor.
Balant, L; Dornier, C; Gex-Fabry, M; Ivancevic, MK; Meier, PJ; Pastor, CM; Planchamp, C; Pochon, S; Quadri, R; Reist, M; Stieger, B; Terrier, F; Vallée, JP, 2004
)
0.32
"07 microg/kg (4 days after the fourth dose) and a half-life of 4 days for antimony elimination from the bone marrow."( Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Costa Val, AP; Demicheli, C; Frézard, F; Melo, MN; Michalick, MS; Rocha, OG; Schettini, DA; Souza, LF, 2005
)
0.33
" We hypothesized that there are age-dependent pharmacokinetic differences of potential clinical relevance."( Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.
Cruz, A; Herwaldt, BL; Palacios, R; Rainey, PM; Saravia, NG; Stagni, G; Trujillo, R, 2007
)
0.34
"001), a 16% lower peak concentration (32."( Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.
Cruz, A; Herwaldt, BL; Palacios, R; Rainey, PM; Saravia, NG; Stagni, G; Trujillo, R, 2007
)
0.34
"The value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in characterizing breast lesions on magnetic resonance imaging (MRI) was evaluated."( Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions.
Barentsz, JO; Blickman, JG; Boetes, C; Huisman, HJ; Mann, R; Stoutjesdijk, M; Veltman, J, 2008
)
0.35
" Additionally, quantitative pharmacokinetic parameters were measured in muscle tissues by applying 3 separate 2-compartment models; (1) artery input function (AIF) based Tofts model, (2) Brix model without AIF, and (3) AIF decomposed refined Brix model."( Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Jia, G; Knopp, MV; Liang, J; Sammet, S; Takayama, Y; Yang, X, 2010
)
0.36
" Among all the quantitative pharmacokinetic parameters, only the exchange rate constants (kep) calculated from these 3 models did not show a significant difference among the various contrast agents."( Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Jia, G; Knopp, MV; Liang, J; Sammet, S; Takayama, Y; Yang, X, 2010
)
0.36
" The observed enhancement characteristics for the 3 contrast agents demonstrate that the pharmacokinetic parameter kep is more robust in various models using DCE-MRI than the other pharmacokinetic parameters."( Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Jia, G; Knopp, MV; Liang, J; Sammet, S; Takayama, Y; Yang, X, 2010
)
0.36
" Gadoterate meglumine half-life in the different compartments was estimated with one- and two-compartment models."( Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice.
Autret, G; Balvay, D; Clément, O; Cuénod, CA; Mühler, MR; Salomon, LJ; Siauve, N; Vayssettes, C, 2011
)
0.37
" The placental gadolinium concentration showed two-compartmental decay, with a first half-life of distribution of 47 minutes and a second half-life of elimination of 107 hours."( Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice.
Autret, G; Balvay, D; Clément, O; Cuénod, CA; Mühler, MR; Salomon, LJ; Siauve, N; Vayssettes, C, 2011
)
0.37
"The purpose of this article is to evaluate the incremental value of pharmacokinetic analysis of dynamic contrast-enhanced (DCE) MRI compared with conventional breast MRI (morphology plus kinetic curve type analysis) in characterizing breast lesions as malignant or benign."( 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
Bluemke, DA; El Khouli, RH; Jacobs, MA; Kamel, IR; Macura, KJ, 2011
)
0.37
" Morphologic features (margin, enhancement, and pattern) and conventional DCE-MRI results (kinetic curve types 1, 2, or 3) or pharmacokinetic parameters (forward volume transfer constant [K(trans)], reverse volume transfer constant [K(ep)], and the extravascular extracellular space volume per unit volume of tissue), were included in multivariate models for prediction of benign versus malignant diagnosis."( 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
Bluemke, DA; El Khouli, RH; Jacobs, MA; Kamel, IR; Macura, KJ, 2011
)
0.37
" For DCE-MRI, both pharmacokinetic modeling and kinetic curve type analysis improved characterization of malignant and benign breast lesions."( 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
Bluemke, DA; El Khouli, RH; Jacobs, MA; Kamel, IR; Macura, KJ, 2011
)
0.37
"The use of kinetic curve type assessment or pharmacokinetic modeling in conjunction with high-resolution 3D breast MRI appears to offer similar improvement in diagnostic performance."( 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
Bluemke, DA; El Khouli, RH; Jacobs, MA; Kamel, IR; Macura, KJ, 2011
)
0.37
"The objective of this study was to evaluate a novel pharmacokinetic approach integrating a tumor model in a whole-body pharmacokinetic model to simulate contrast media-induced signal intensity time curves of breast tumors on dynamic contrast-enhanced magnetic resonance mammography."( Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Bick, U; Böttcher, J; Diekmann, F; Durmus, T; Fallenberg, EM; Hamm, B; Huppertz, A; Lawaczeck, R; Pietsch, H; Renz, DM; Schmitzberger, FF, 2013
)
0.39
"A recently developed, whole-body pharmacokinetic model, which describes the distribution and excretion of renally discharged contrast media, has been expanded by integrating a tumor model."( Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Bick, U; Böttcher, J; Diekmann, F; Durmus, T; Fallenberg, EM; Hamm, B; Huppertz, A; Lawaczeck, R; Pietsch, H; Renz, DM; Schmitzberger, FF, 2013
)
0.39
" According to the pharmacokinetic approach, the variation of the Vblood/kt ratio, which defined the tumor flow residence time τr, led to Gd concentration time curves congruent with the shapes of the measured signal intensity time curves."( Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Bick, U; Böttcher, J; Diekmann, F; Durmus, T; Fallenberg, EM; Hamm, B; Huppertz, A; Lawaczeck, R; Pietsch, H; Renz, DM; Schmitzberger, FF, 2013
)
0.39
"On the basis of this pharmacokinetic model, the contrast media-induced time curves on dynamic contrast-enhanced magnetic resonance mammography can be classified by a single kinetic parameter, the tumor flow residence time τr, into benign (τr >200 seconds) and malignant (τr <200 seconds) curve shapes."( Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Bick, U; Böttcher, J; Diekmann, F; Durmus, T; Fallenberg, EM; Hamm, B; Huppertz, A; Lawaczeck, R; Pietsch, H; Renz, DM; Schmitzberger, FF, 2013
)
0.39
" Quantitative pharmacokinetic perfusion parameters of lumbar and pelvic marrow were analyzed by three readers on a DCE-MRI postprocessing platform."( Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values.
Bashir, MR; Breault, SR; Dale, BM; Faridi, KF; Gupta, RT; Heye, T; Merkle, EM; Reiner, CS, 2013
)
0.39
"To determine the pharmacokinetic profile of gadobenate dimeglumine in children aged between 2 and 5 years."( Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.
Kirchin, MA; Lorusso, V; Patel, R; Pirovano, G; Shen, N, 2015
)
0.42
" Pharmacokinetic parameters were calculated using noncompartmental and compartmental techniques."( Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.
Kirchin, MA; Lorusso, V; Patel, R; Pirovano, G; Shen, N, 2015
)
0.42
"2 h for terminal elimination half-life were determined across all age groups combined."( Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.
Kirchin, MA; Lorusso, V; Patel, R; Pirovano, G; Shen, N, 2015
)
0.42
"To investigate variation in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic parameter measurements between different methods of precontrast tissue relaxation (T10) estimation: pixel-based mapping versus a fixed reference value."( Impact of precontrast T10 relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value.
Bashir, MR; Boll, DT; Dale, BM; Heye, T; Merkle, EM; Reiner, CS, 2014
)
0.4
" Pharmacokinetic measurements of Ktrans, kep, ve, and initial area under the gadolinium curve (iAUGC) were performed maintaining the identical position for region of interest placement on each structure."( Impact of precontrast T10 relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value.
Bashir, MR; Boll, DT; Dale, BM; Heye, T; Merkle, EM; Reiner, CS, 2014
)
0.4
"Direct comparison of pharmacokinetic parameters derived from a pixel-based approach versus a reference value uniformly applied to all pixels for T10 estimation is impeded by the inherent spatial heterogeneity of T10 within tissues."( Impact of precontrast T10 relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value.
Bashir, MR; Boll, DT; Dale, BM; Heye, T; Merkle, EM; Reiner, CS, 2014
)
0.4
"To introduce a segmentation method to calculate an automatic arterial input function (AIF) based on principal component analysis (PCA) of dynamic contrast enhanced MR (DCE-MR) imaging and compare it with individual manually selected and population-averaged AIFs using calculated pharmacokinetic parameters."( Automatic individual arterial input functions calculated from PCA outperform manual and population-averaged approaches for the pharmacokinetic modeling of DCE-MR images.
Alberich-Bayarri, Á; Ferrer, A; García-Martí, G; Martí-Bonmatí, L; Pérez, R; Prats-Montalbán, JM; Sanz-Requena, R, 2015
)
0.42
" The different AIFs were used as inputs to the pharmacokinetic model and correlation coefficients, Bland-Altman plots and analysis of variance tests were obtained to compare the results."( Automatic individual arterial input functions calculated from PCA outperform manual and population-averaged approaches for the pharmacokinetic modeling of DCE-MR images.
Alberich-Bayarri, Á; Ferrer, A; García-Martí, G; Martí-Bonmatí, L; Pérez, R; Prats-Montalbán, JM; Sanz-Requena, R, 2015
)
0.42
"Using a nonconventional pharmacokinetic approach, we showed that gadoterate meglumine undergoes a much faster residual excretion from the body than the linear GBCAs, a process that seems related to the thermodynamic stability of the different chelates."( Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
Lancelot, E, 2016
)
0.43
"The primary objective of this study was to investigate the pharmacokinetic profile of gadoterate meglumine in pediatric patients younger than 2 years; the secondary objectives were to document its efficacy and safety."( A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
Bourrinet, P; de Buttet, S; Felices, M; Jurkiewicz, E; Koob, M; Scala, M, 2018
)
0.48
" Considering the current concept for the evaluation of pharmacokinetic parameters at early phases of drug discovery, we developed a formulation of MA-encapsulated into phosphatidylserine liposomes (MA-LP) and analyzed the in vitro antileishmanial activity, physicochemical properties, and pharmacokinetic profile in a mice model."( Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
Borborema, SET; de Andrade Junior, HF; do Nascimento, N; Osso Junior, JA; Tempone, AG, 2018
)
0.48
"The study successfully identified a Phase III formulation with a reduced SLS content, which when administered following a low-fat meal, gave comparable pharmacokinetic exposure to the Phase I/II formulation administered under the same conditions."( Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Cheeti, S; Chen, B; Gates, M; Girish, S; Hou, HH; Liu, L; Morley, R; Musib, L; Nelson, E; Sahasranaman, S; Walker, H, 2018
)
0.48

Compound-Compound Interactions

In vitro, Z-100 alone or combined with meglumine antimoniate showed an antileishmanial effect on L.BALB/c mice. The LEISH-F1+MPL-SE vaccine was safe and immunogenic in CL patients and appeared to shorten their time to cure.

ExcerptReferenceRelevance
" Patients were randomized to receive either GM-CSF, 5 micrograms/kg daily (intravenously or subcutaneously), or placebo for ten days, in combination with pentavalent antimony, 10-20 mg/kg daily for 20 days."( Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.
Badaró, F; Badaró, R; Carvalho, JS; Ho, JL; Johnson, WD; Jones, TC; Nascimento, C; Reed, SG; Russo, D, 1994
)
0.29
"BALB/c mice with an experimental visceral leishmaniasis produced by Leishmania infantum were treated with aminosidine sulphate alone or combined with meglumine antimoniate."( Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Derouin, F; Gangneux, JP; Garin, YJ; Sulahian, A, 1997
)
0.3
"Bladder cancer cells were exposed to MeEPA in combination with epirubicin or mitomycin."( Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.
Cooper, AJ; Harris, NM; Lwaleed, BA; Mackie, SJ; Sharma, DM, 2006
)
0.33
"To determine the efficacy and safety of imiquimod in combination with meglumine antimoniate in treating cutaneous leishmaniasis."( Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Dowlati, Y; Eskandari, SE; Firooz, A; Ghoorchi, MH; Gorouhi, F; Hooshmand, B; Khamesipour, A; Khatami, A; Nassiri-Kashani, M; Rashighi-Firoozabadi, M, 2006
)
0.33
"To determine the efficacy and the immunomodulatory function of Z-100 alone or combined with meglumine antimoniate on Leishmania amazonensis infection."( A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso, PA; Calvopina, M; Hashiguchi, Y; Kato, H; Korenaga, M; Marco, JD, 2007
)
0.34
" The objective of this study was to compare the clinical efficacy of intramuscular pentavalent antimonial compound meglumine antimoniate alone and in combination with intralesional therapy in the treatment of Old World cutaneous leishmaniasis."( Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Hussain, I; Janjua, SA; Munir, A, 2008
)
0.35
" The LEISH-F1+MPL-SE vaccine was safe and immunogenic in CL patients and appeared to shorten their time to cure when used in combination with meglumine antimoniate chemotherapy."( A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Alves, FP; Ashman, JA; Beckmann, AM; Bogatzki, LY; Campos-Neto, A; Coler, RN; Cowgill, KD; Fernandes, DF; Kahn, SJ; Nascimento, E; Piazza, FM; Pine, SO; Reed, SG; Vieira, EP, 2010
)
0.36
"Effectivity of detoxic preparation reamberin at complex treatment of the patients with acuting of chronic cholecystitis combined with chronic pancreatitis on background of HCV-infection was detected."( [Effectivity of detoxification preparation reamberin in complex treatment of the patients with chronic cholecystitis combined with chronic pancreatitis on background of HCV-infection].
Frolov, VM; Kruglova, OV; Sanzharevskaia, IV; Sotskaia, IaA,
)
0.13
" Simultaneous drug-drug interactions through uptake and efflux transport systems in hepatocytes according to the cellular concentrations of competing drugs were never investigated."( Evidence of drug-drug interactions through uptake and efflux transport systems in rat hepatocytes: implications for cellular concentrations of competing drugs.
Daali, Y; Dayer, P; Millet, P; Pastor, CM, 2013
)
0.39
"MA) either alone or combined with application of a silver or a non-silver polyester dressing on their lesions for 6 weeks."( Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
Dowlati, Y; Firooz, A; Khamesipour, A; Khatami, A; Mehryan, P; Rahshenas, M; Talaee, R; Tehrani, S, 2013
)
0.39
"A successful administration of NPWT-therapy combined with Reamberin infusion for gastroenterostomy failure after stomach resection is reported in the article."( [Npwt-therapy combined with reamberin infusion for gastroenterostomy failure after stomach resection].
Larin, VV; Miklichev, AA; Varganov, MV, 2019
)
0.51
" In this study, we aim to explore the clinical efficacy of ulinastatin combined with meglumine adenosine cyclophosphate in patients with acute myocardial infarction (AMI) and its effect on cardiac function and endothelial function of patients."( Clinical Efficacy of Ulinastatin Combined with Meglumine Adenosine Cyclophosphate in the Treatment of Acute Myocardial Infarction.
Cao, Q; Ma, J; Ma, Q; Sun, X; Wang, L; Zhang, L; Zhang, Z, 2022
)
0.72

Bioavailability

Previous studies have shown that the association of the drug meglumine antimoniate (MA) with β-cyclodextrin can improve its bioavailability by the oral route. In this study, a novel rebamipide-loaded spray-dried microsphere (RSM) with enhanced drug solubility and oral bioavailability has been developed.

ExcerptReferenceRelevance
" The apparent bioavailability of antimony was > 100 per cent for the intramuscular and 100 per cent for the subcutaneous routes."( Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog.
Belloli, C; Carli, S; Ceci, L; De Natale, G; Madonna, M; Marcotrigiano, GO; Ormas, P; Tassi, P, 1994
)
0.29
" The pharmacokinetic parameters and bioavailability of antimony were calculated after each route of administration in each dog."( Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
Alberola, J; Arboix, M; Esteban, M; Valladares, JE, 1996
)
0.29
"The efficiency of antileishmanial agents may be enhanced by improving their bioavailability with a colloidal drug carrier."( Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model.
Astier, A; Bories, C; Deniau, M; Durand, R; Fusai, T; Houin, R; Paul, M; Rivollet, D, 1994
)
0.29
" This improved physicochemical behavior of ternary complex with the novel inclusion of a polyhydroxy base translated into an enhanced oral bioavailability of DRF-4367 compared with either uncomplexed drug or nanosuspension."( Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxy propyl-beta-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component.
Basavaraj, S; Kumar Singh, S; Ramesh, M; Shantha Kumar, TR; Sihorkar, V; Srinivas, NR; Sundaramurthi, P; Venkatesh, P, 2006
)
0.33
" This unexpected behaviour was attributed, in part, to the fact that the heating of equimolar mixture of MA and beta-CD (first step of preparation of MA/beta-CD composition) induced the depolymerization of MA from high-molecular weight Sb complexes into 1:1 Sb-meglumine complex, resulting in an enhanced oral bioavailability of Sb."( Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies.
Bahia, AP; da Silva, JB; de Melo, AL; Demicheli, C; Frézard, F; Le Moyec, L; Martins, PS; Pimenta, AM; Salerno, M, 2008
)
0.35
"Twenty-two patients with ICD underwent contrast-enhanced cardiac MRI with a specific absorption rate of <2."( MRI-Guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators.
Ahmad, G; Dickfeld, T; Jeudy, J; Jimenez, A; Kuk, R; Peters, M; Saba, M; Saliaris, A; Shorofsky, S; Tian, J; Turgeman, A, 2011
)
0.37
"To investigate the use of radiofrequency (RF) gating in conjunction with a paramagnetic contrast agent to reduce the specific absorption rate (SAR) and increase the blood-myocardium contrast in balanced steady-state free precession (bSSFP) 3D cardiac cine."( Contrast-enhanced specific absorption rate-efficient 3D cardiac cine with respiratory-triggered radiofrequency gating.
Botnar, RM; Chan, RH; Goddu, B; Goepfert, LA; Henningsson, M; Nezafat, R; Razavi, R; Schaeffter, T, 2013
)
0.39
" In conclusion, it is possible to increase the bioavailability of poorly soluble drugs by preparing its water-soluble derivative."( In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative.
Li, LC; Mao, S; Ni, R; Sun, W; Xu, D, 2015
)
0.42
"Previous studies have shown that the association of the drug meglumine antimoniate (MA) with β-cyclodextrin can improve its bioavailability by the oral route."( Mixed antimony(V) complexes with different sugars to modulate the oral bioavailability of pentavalent antimonial drugs.
Andrade, AP; Demicheli, C; Fernandes, FR; Ferreira, WA; Frézard, F; Islam, A, 2014
)
0.4
" The main objective of the present work was to interfere in the structural organization of these nanoassemblies so as to investigate their influence on the oral bioavailability of Sb, and ultimately, optimize an oral formulation of SbL8 for the treatment of cutaneous leishmaniasis."( Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
Andrade, MS; Corrêa-Júnior, JD; Demicheli, C; Fernandes, FR; Ferreira, LA; Frézard, F; Lanza, JS; Magalhães-Paniago, R; Melo, MN; Vilela, JM, 2016
)
0.43
"Generally, the optimized ternary cyclodextrin complexation might be a potential formulation strategy for enhancing the solubility and bioavailability of poorly water-soluble ST-246."( Formulation and Characterization of a Ternary Inclusion Complex Containing Hydroxypropyl-β-cyclodextrin and Meglumine for Solubility Enhancement of Poorly Water-Soluble ST-246, an Anti-Smallpox Drug.
Gao, C; Gong, W; Li, X; Li, Y; Shan, L; Shao, S; Wang, Y; Yang, M; Zhong, W, 2017
)
0.46
"Here, solid dispersion (SD) techniques were utilized to improve the oral bioavailability of tadalafil (TDF)."( Tadalafil solid dispersion formulations based on PVP/VA S-630: Improving oral bioavailability in rats.
Byeon, JC; Choi, JS; Jang, WS; Lee, SE; Park, JS, 2017
)
0.46
"In this study, a novel rebamipide-loaded spray-dried microsphere (RSM) with enhanced drug solubility and oral bioavailability has been developed utilizing meglumine, an alkalizing agent."( Development of rebamipide-loaded spray-dried microsphere using distilled water and meglumine: physicochemical characterization and pharmacokinetics in rats.
Cho, JH; Choi, HG; Ko, DW, 2021
)
0.62
"Silybin (SLB) as an effective hepatoprotective phytomedicine has been limited by its hydrophobicity, poor bioavailability and accumulation at lesion sites."( Combined Amphiphilic Silybin Meglumine Nanosuspension Effective Against Hepatic Fibrosis in Mice Model.
Chen, D; Feng, J; Gong, T; Guo, C; He, Q; Li, J; Song, X; Tan, T; Tan, Y; Yang, Q, 2023
)
0.91

Dosage Studied

First-line therapy was meglumine antimoniate for all patients, given at the standard Sb(v) dosage of 20 mg/kg/day for 21 to 28 days. NSF does not appear to occur in patients with stage 3 chronic kidney disease exposed to intravenous gadobenate dime glumine.

ExcerptRelevanceReference
"The present study was carried out to investigate the time course of metabolization in brain and the influence on RNA synthesis of a retention-improving dosage of methylglucamine orotate after intracerebroventricular application."( Metabolization of a retention-improving dosage of methylglucamine orotate in rat brain.
Matthies, H; Popov, N; Staak, S; Tischmeyer, W, 1990
)
0.28
" braziliensis LTB259) a dose-response line is obtained at a higher concentration range (20 mM to 70 mM)."( In vitro activity of meglumine antimoniate, a pentavalent antimonial drug, on Leishmania promastigotes.
Moreira, ES; Petrillo-Peixoto, ML, 1991
)
0.28
" Treatment with meglumine antimoniate (Glucantime) administered iv at a dosage of 20 mg antimony/kg body weight/day for 60 days resulted in visible improvement of the lesions, but not in clinical or parasitological cure."( Diffuse cutaneous leishmaniasis acquired in Peru.
De Rivera, MV; Franke, ED; Kruger, JH; Lucas, CM; Tovar, AA; Wignall, FS, 1990
)
0.28
" These may be prevented by respecting the maximal suggested dosage of 6 cg/kg/day, regular clinical checks of pulse, blood pressure and temperature, biological follow-up of serum creatinin, transaminases and routine electrocardiography."( [Toxicity of Glucantime. A case].
Ben Salah, N; Katlama, C; Pichard, E; Régnier, B; Vachon, F, 1985
)
0.27
" With this latter dosage or with 104 mg/kg/day there was no acute toxicity of formycin B to bone marrow or formed elements of the blood."( Leishmania donovani: oral efficacy and toxicity of formycin B in the infected hamster.
Berman, JD; Hanson, WL; Keenan, CM; Lamb, SR; Waits, VB, 1983
)
0.27
" Seemingly, liposomes can markedly reduce the drug dosage required for equivalent treatment of visceral leishmaniasis in dogs."( Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Alving, CR; Chapman, WL; Hanson, WL; Hendricks, LD, 1984
)
0.27
" A dosage of 25 to 50 mg/kg/day of N-Methyl-glucamine in two or three treatment series, produced the healing of the cutaneous sore, without electrocardiographic alterations which could be interpreted as signs of myocardial toxicity."( [Electrocardiographic evaluation of the cardiotoxicity of N-methylglucamine antimonate (R glucantime)].
Carrasco, H; Fuenmayor, A; García Muller, R; Mendoza, E; Ramírez Benedetti, J; Torrealba, W; Valera, M,
)
0.13
" These results indicate that distinct and contrasting dose-response profiles exist for these classical and atypical drugs in an animal model of anxiety based on electric shock."( Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.
Dooley, DJ; Klamt, I, 1993
)
0.29
") were administered 30 min before determination of cocaine dose-response functions using a cumulative dosing method."( Effects of cholecystokinin antagonists on the discriminative stimulus effects of cocaine in rats and monkeys.
Massey, BW; Vanover, KE; Woolverton, WL, 1994
)
0.29
") schedule, especially when a low dosage of Glucantime (30 mg/kg/d x 20 d) was used."( Antimonial treatment of hamsters infected with Leishmania (Viannia) panamensis: assessment of parasitological cure with different therapeutic schedules.
Martinez, JE; Travi, BL; Zea, A,
)
0.13
" At each dosage investigated, the changes associated with the administration of gadodiamide injection were of significantly smaller magnitude than those seen after gadopentetate dimeglumine and returned to preadministration levels sooner."( Hemodynamic effects of gadodiamide injection and gadopentetate dimeglumine in anesthetized dogs.
Peters, JL; Shaw, DD, 1993
)
0.29
") did not shift the apomorphine dose-response curve (0."( Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
Christoffersen, CL; Meltzer, LT; Razmpour, A; Serpa, KA, 1993
)
0.29
"Compliance with an institution's dosage guidelines for gadoteridol was determined, and adverse reactions to gadoteridol and gadopentetate were compared."( Dosage of gadoteridol and adverse reactions relative to gadopentetate.
Hieronim, DE; Kanal, E; Swanson, DP, 1995
)
0.29
" Contrast-to-noise ratio was not affected by the dosage level."( Assessment of acute myocardial infarction in man with magnetic resonance imaging and the use of a new paramagnetic contrast agent gadolinium-BOPTA.
de Roos, A; Doesburg, T; Holman, ER; van der Wall, EE; van Rossum, AC; Visser, CA, 1996
)
0.29
" The dose-response relationship of a new, potent and selective cholecystokinin B receptor antagonist, CI-988, on the growth of LoVo, a human colon cancer cell line, was studied in vivo."( Dose dependent in vivo inhibition of human colorectal cancer (LoVo) by the gastrin receptor antagonist, CI-988.
Howes, LG; Morris, DL; Romani, R, 1996
)
0.29
" The dose-response curve for RB 101 was shifted to the left and the duration of reflex depression was significantly prolonged."( CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
Elfvin, A; Fournié-Zaluski, MC; Hao, JX; Roques, BP; Wiesenfeld-Hallin, Z; Xu, XJ, 1997
)
0.3
" In 10 out of 12 patients receiving a dose of 5 mg/kg/day and 9 out of 11 patients with a dosage of 20 mg/kg/day a complete epithelization was noted by the end of treatment."( Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
Gonçalves-Costa, SC; Mattos, M; Oliveira-Neto, MP; Pirmez, C; Schubach, A, 1997
)
0.3
" High-dose monkeys were dosed initially at 100 mg/kg, but the dose was not well tolerated and was decreased to 75 mg/kg after 8 days of treatment."( Gastric gland degeneration induced in monkeys by the CCK-B/gastrin receptor antagonist CI-988.
Bestervelt, LL; Breider, MA; Dethloff, LA; Robertson, DG; Tierney, BM,
)
0.13
" This rightward shift of the morphine dose-response curve was reversed by the intrathecal administration of either the CCKA receptor antagonist, lorglumide, or the CCKB receptor antagonist, PD135, 158."( Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin.
Fujimoto, JM; Lin, W; Rady, JJ, 1998
)
0.3
"8 micrograms ml-1 found after this dosage regimen were higher than those observed after the single dose administration of 100 mg kg-1 24 h-1."( Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Alberola, J; Arboix, M; Cristòfol, C; Franquelo, C; Gállego, M; Portús, M; Riera, C; Valladares, JE, 1998
)
0.3
" Unfortunately, pharmacokinetics and optimal dosage of diamidines are not well-known, and numerous adverse events are described."( [Treatment of infantile visceral leishmaniasis].
Dumon, H; Faraut-Gambarelli, F; Garnier, JM; Gire, C; Minodier, P; Piarroux, R, 1999
)
0.3
" Morphine analgesia was inhibited by dynorphin as shown by a rightward shift of the morphine dose-response curve."( Antianalgesic action of dynorphin A mediated by spinal cholecystokinin.
Fujimoto, JM; Holmes, BB; Rady, JJ, 1999
)
0.3
" For both GLA salts, cytotoxicity was manifested after 4 days of cell exposure and with very sharp dose-response curves."( Cytotoxic effects of two gamma linoleic salts (lithium gammalinolenate or meglumine gammalinolenate) alone or associated with a nitrosourea: an experimental study on human glioblastoma cell lines.
Bryce, R; Etienne, MC; Ferrero, JM; Fischel, JL; Formento, P; Ilc, K; Milano, G, 1999
)
0.3
" Few data are available on the toxicity and efficacy of these drugs at the dosing schedule recommended by the Centers for Disease Control and Prevention (CDC) (Atlanta, GA)."( High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Corzo, JE; de la Rosa, R; Delgado, J; González-Moreno, MP; Leal, M; Lissen, E; Macías, J; Pineda, JA; Sánchez-Quijano, A, 1999
)
0.3
" An increase in relative liver and kidney weights was recorded for males and females dosed at 6 mmol/kg."( [General toxicity study of gadobenate dimeglumine formulation (E7155) (2)--Single dose intravenous toxicity study in dogs].
Bussi, S; Masters, RE; Morisetti, A; Sagami, F; Sekido, T; Tirone, P, 1999
)
0.3
" Vacuolation of renal tubular cells was common, expected, and known as an adaptive change of treatment with hypertonic solutions, and an increase in the incidence of local damage at the injection sites was due to irritation by repeated intravenous dosing with hypertonic solutions."( [General toxicity study of gadobenate dimeglumine formulation (E7155) (3)--4-week repeated dose intravenous toxicity study followed by 4-week recovery period in rats].
Aoki, T; Bussi, S; Masters, RE; Morisetti, A; Sagami, F; Tirone, P, 1999
)
0.3
" Although pentavalent antimonials (Sb5+) are the mainstay of leishmanial therapy and have been used for more than 50 years, dosage regimens have been repeatedly modified and the best one has not been fully identified."( Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
Andrade-Narvaez, FJ; Canto-Lara, SB; Damian-Centeno, AG; Vargas-Gonzalez, A, 1999
)
0.3
" The order of dosage was randomized, with both the physician and patient blinded to the administered dose."( Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging.
Kenney, CM; Runge, VM, 2000
)
0.31
" Animals dosed with RB 120 (10 mg/kg) failed to develop a discriminative response."( Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties.
Fournié-Zaluski, M; Hutcheson, DM; Maldonado, R; Pache, DM; Roques, BP; Sewell, RD; Subhan, F, 2000
)
0.31
" A dosage of 30-90 mL was used."( Gadolinium-based contrast: an alternative contrast agent for endovascular interventions.
Ferreira, LM; Parodi, JC, 2000
)
0.31
" Nine days after the dose, meglumine antimoniate was reintroduced at a dosage of 11."( Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy.
Hantson, P; Haufroid, V; Lambert, M; Luyasu, S, 2000
)
0.31
" We developed a simple and reliable microassay based on N-ribohydrolase dosage using 4-nitrophenyl-beta-D-ribofuranoside (NPR) substrate for the quantification of Leishmania infantum."( Assessment of Leishmania promastigote growth in vitro by means of nucleoside hydrolase activity determination.
Derouin, F; Gangneux, JP; Garin, YJ; Meneceur, P; Pannier-Stockman, C; Sulahian, A, 2001
)
0.31
" Patients were randomized to one of three incremental dosing regimens."( A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Armstrong, MR; Barr, RG; Berger, BL; Czervionke, LF; Gonzalez, CF; Halford, HH; Kanal, E; Kuhn, MJ; Levin, JM; Low, RN; Runge, VM; Tanenbaum, LN; Wang, AM; Wong, W; Yuh, WT; Zoarski, GH, 2001
)
0.31
" Both reviewers found the level of diagnostic information to be equivalent after the second dose of contrast for all three dosing regimens."( A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Armstrong, MR; Barr, RG; Berger, BL; Czervionke, LF; Gonzalez, CF; Halford, HH; Kanal, E; Kuhn, MJ; Levin, JM; Low, RN; Runge, VM; Tanenbaum, LN; Wang, AM; Wong, W; Yuh, WT; Zoarski, GH, 2001
)
0.31
"To determine the dosage of gadobenate dimeglumine (Gd-BOPTA) necessary for MRI of rheumatoid arthritis of the wrist."( MR imaging of the wrist in rheumatoid arthritis using gadobenate dimeglumine.
Bonél, HM; Huegli, R; Lodemann, KP; Reiser, M; Schneider, P; Seemann, MD; Srivastav, S, 2001
)
0.31
" Three-dimensional T1-weighted gradient-recalled echo sequences (GRE; TR: 100 ms, TE: 18 ms, flip angle 90 degrees , 4:55 min) were acquired prior to an intravenous injection and after each additional dosage of Gd-BOPTA."( MR imaging of the wrist in rheumatoid arthritis using gadobenate dimeglumine.
Bonél, HM; Huegli, R; Lodemann, KP; Reiser, M; Schneider, P; Seemann, MD; Srivastav, S, 2001
)
0.31
" In vitro drug resistance was evaluated and the comparative analyses of dose-response curves showed that the susceptibility pattern of the sensitive line did not change after passage in animals, but a decrease in drug resistance was observed in resistant cell lines recovered from the mammalian host."( Cell surface carbohydrates and in vivo infectivity of glucantime-sensitive and resistant Leishmania (Viannia) guyjanensis cell lines.
Anacleto, C; Andrade, AF; Ferreira, AV; Gazola, KC; Michalick, MS; Moreira, ES, 2001
)
0.31
" Patients were randomized to one of three incremental dosing regimens."( Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Donovan, M; Parker, JR; Runge, VM, 2002
)
0.31
" In between-group comparisons, the level of diagnostic information was similar after the first contrast dose for all three dosing regimens."( Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Donovan, M; Parker, JR; Runge, VM, 2002
)
0.31
" Single dosage of the used new contrast agents was sufficient to achieve high quality perfusion maps."( [Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers].
Essig, M; Hübener, M; LeHuu, M; Lodemann, KP; Schönberg, SO; Van Kaick, G, 2002
)
0.31
" This gadobutrol dosage was then diluted with saline into twice the volume and administered as a bolus at twice the injection rate."( Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography.
Bosk, S; Debatin, JF; Goyen, M; Herborn, CU; Lauenstein, TC; Ruehm, SG, 2003
)
0.32
" Dogs of group 1 were treated by use of meglumine antimonate (100 mg/kg, SC, q 24 h) administered concurrently with allopurinol (15 mg/kg, PO, q 12 h) for 20 days and then with allopurinol alone at the same dosage for the subsequent 30 days."( Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment.
Bernal, LJ; Cerón, JJ; Martínez-Subiela, S, 2003
)
0.32
" Both had symptomatic relapses 3 months later, and recovered following re-treatment with AmBisome administered intravenously at a dosage of 3 mg/Kg for ten consecutive days."( [Mediterranean visceral leishmaniasis in immunocompetent children. Report of two cases relapsed after specific therapy].
Colomba, C; Frasca Polara, V; Salsa, L; Scarlata, F; Titone, L, 2004
)
0.32
" Ten were treated with meglumine antimonate (20 mg/kg/day for 21 days) and remained in hospital for 11-28 days (median 19 days), while 19 patients received liposomal amphotericin B at four different dosage schemes and were in hospital for 6-11 days (median 7 days)."( Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Delis, D; Kafetzis, DA; Liapi, G; Mavrikou, M; Stabouli, S; Velissariou, IM, 2005
)
0.33
"To prospectively assess a dose-response relationship for small volumes of liver parenchyma after single-fraction irradiation."( In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation.
Al-Abadi, H; Cho, CH; Felix, R; Hengst, S; Lopez Hänninen, E; Lüdemann, L; Mohnike, K; Pech, M; Ricke, J; Seidensticker, M; Wieners, G; Wust, P, 2005
)
0.33
"05 mmol/kg bw of Gd-BOPTA and a superior image quality for both dosage regimen compared with the other sequences and was consequently applied for the main study."( Determinants of myocardial response in CMR perfusion imaging using Gd-BOPTA (Multihance).
Bornstedt, A; Fleck, E; Gebker, R; Gomaa, O; Jahnke, C; Nagel, E; Neuss, M; Paetsch, I; Schnackenburg, B, 2005
)
0.33
" The evaluation of clinical trials provided good evidence for recommending the use of meglumine antimoniate at a minimum dosage of 100 mg kg(-1) daily for at least 3-4 weeks, combined with allopurinol in order to obtain a good clinical efficacy and a reduced relapse rate."( Treatment of canine Old World visceral leishmaniasis: a systematic review.
Auxilia, ST; Noli, C, 2005
)
0.33
" Thus, the clear aceclofenac-loaded soft capsule with ethanolamine was a more effective oral dosage form with fast absorption for poorly water-soluble aceclofenac."( Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects.
Choi, HG; Gil, YS; Kim, CK; Kim, JO; Lee, KH; Oh, YK; Park, SM; Park, YJ; Rhee, JD; Woo, JS; Yong, CS; Yoo, BK; Yu, CH, 2005
)
0.33
" At the used small injection volumes, the tissue concentration curve was determined only by the gadolinium (Gd) dosage in mmol/kg, and the T2* relaxation effects of the two agents can be considered to be nearly identical in the applied gradient-echo (GRE) sequence."( Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.
Björkman-Burtscher, IM; Larsson, EM; Ståhlberg, F; Thilmann, O; Wirestam, R, 2005
)
0.33
"Despite more than half a century of use in leishmaniasis, antimony therapy still presents serious problems concerning dosage and toxicity."( An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable.
de Oliveira-Neto, MP; Mattos, Mda S,
)
0.13
" Hydroxyurea completely eliminated Leishmania parasites when it was used at a dosage of 10 or 100 microg/ml."( Activity of hydroxyurea against Leishmania mexicana.
Galindo-Sevilla, N; Mancilla-Ramirez, J; Martinez-Rojano, H; Quiñonez-Diaz, L, 2008
)
0.35
"To prospectively assess a dose-response relationship for the hepatic reticulo-endothelial system (RES) after small volume single fraction irradiation of liver parenchyma in vivo."( Assessment of the tolerance dose of the hepatic reticulo-endothelial system (RES) after single fraction HDR-irradiation: an in-vivo study employing SSPIO.
Mohnike, K; Pech, M; Ricke, J; Ruhl, R; Seidensticker, M; Seidensticker, P; Staskiewicz, G; Steinberg, J; Wieners, G; Wust, P, 2008
)
0.35
"At the dosage used in this study, Gd-BOPTA yields higher maximum enhancement of the hepatic artery, portal vein, and middle hepatic vein during the arterial and the portal venous phase and during the delayed phases than Gd-EOB-DTPA does, whereas there is no difference in liver parenchymal enhancement between the two contrast agents."( Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Albiin, N; Brismar, TB; Dahlstrom, N; Edsborg, N; Persson, A; Smedby, O, 2009
)
0.35
" The possibility was investigated in this study that pharmaceutical excipients commonly used in oral solid dosage forms might also be sources of formaldehyde."( Generation of formaldehyde by pharmaceutical excipients and its absorption by meglumine.
Fujita, M; Handa, T; Ueda, T, 2009
)
0.35
" Growth curves supported the dose-response observations."( Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA, 2010
)
0.36
" First-line therapy was meglumine antimoniate for all patients, given at the standard Sb(v) dosage of 20 mg/kg/day for 21 to 28 days."( Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995-2009).
Foto, E; Gradoni, L; Kuneshka, L; Petrela, R; Zavalani, F, 2010
)
0.36
"Poor dissolution performance is one of the challenges encountered in dosage form design of amorphous solid dispersions (ASDs)."( Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion.
Bansal, AK; Dantuluri, AK; Puri, V, 2011
)
0.37
"Amorphous solid dispersions (ASDs) may entail tailor-made dosage form design to exploit their solubility advantage."( Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
Bansal, AK; Dantuluri, AK; Puri, V, 2012
)
0.38
"Antimony (Sb) disposition and toxicity was evaluated in Leishmania braziliensis-infected monkeys (Macaca mulatta) treated with a 21-d course of low (LOW) or standard (STD) meglumine antimoniate (MA) dosage regimens (5 or 20 mg Sb(V)/kg body weight/d im)."( Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
Friedrich, K; Grimaldi, G; Marchevsky, RS; Miekeley, N; Paumgartten, FJ; Porrozzi, R; Vieira, FA, 2012
)
0.38
"For any new vaginal dosage form, the distribution and retention in the vagina has to be assessed by in vivo evaluation."( Vaginal distribution and retention of a multiparticulate drug delivery system, assessed by gamma scintigraphy and magnetic resonance imaging.
De Vos, F; Mehta, S; Mehuys, E; Peremans, K; Remon, JP; Vermeire, S; Verstraelen, H; Vervaet, C; Villeirs, G, 2012
)
0.38
"Four different approaches were followed for the development of a HPLC method for the determination of meglumine in solid dosage formulations: derivatization of meglumine prior to HPLC analysis, the use of an ion-pairing reagent in the mobile phase, the use of charged surface hybrid stationary phase and the use of a column designed for carbohydrate separations."( Determination of meglumine in pharmaceutical formulations using high performance liquid chromatography.
Cetina-Cizmek, B; Dragić, T; Jasprica, I; Mrsić, N, 2011
)
0.37
"A total of 12 experimental animals were evaluated using equivalently dosed gadobutrol and Gd-DOTA for time-resolved and static imaging."( Magnetic resonance evaluation of renal artery stenosis in a swine model: performance of low-dose gadobutrol versus gadoterate meglumine in comparison with digital subtraction intra-arterial catheter angiography.
Ai, F; Attenberger, UI; Lennox, M; Li, X; McNeal, G; Miller, M; Morelli, JN; Runge, VM; Schmitt, P; Schoenberg, SO; Wusten, O; Zhang, W, 2012
)
0.38
" Scans using equivalently dosed (on a per mmol basis) gadobutrol and gadoterate meglumine were compared qualitatively and quantitatively in terms of contrast-to-noise ratio (CNR)."( MR angiography of carotid artery aneurysms in a porcine model at 3 Tesla: comparison of two different macrocyclic gadolinium chelates and of dynamic and conventional techniques.
Cotes, C; Fossum, TW; Krombach, GA; Lenox, MW; Miller, MW; Morelli, JN; Runge, VM; Trelles, M; Tuzun, E; Wuesten, O, 2012
)
0.38
"5 M gadolinium-based contrast agents (GBCA) using equimolar dosing in dynamic and static magnetic resonance angiography (MRA) of the supra-aortic vessels."( Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose.
Arnoldi, E; François, CJ; Grist, TM; Kramer, JH; Nikolaou, K; Wentland, AL; Wintersperger, BJ, 2013
)
0.39
" The greater relaxation enhancement and more favorable dosing profile make blood-pool agents superior to standard agents for use in cerebral time-resolved MRA."( Improved quality and diagnostic confidence achieved by use of dose-reduced gadolinium blood-pool agents for time-resolved intracranial MR angiography.
Dehkharghani, S; Kang, J; Saindane, AM, 2014
)
0.4
" Data were collected on age, sex, origin, method of diagnosis, adverse effects of drugs, duration of hospitalization, duration of treatment and dosage up to the onset of adverse effects."( Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Pedrosa, CM; Ribeiro, SA; Rocha, TJ; Silveira, LJ,
)
0.13
" The dosage and duration of treatment with Glucantime were consistent with that advocated by the Ministry of Health."( Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Pedrosa, CM; Ribeiro, SA; Rocha, TJ; Silveira, LJ,
)
0.13
"This work provides validated mathematical expressions for contrast enhanced T1-weighted SGRE imaging and may provide guidance for contrast dosing and injection protocols, as well as for novel pulse sequence design."( Mathematical optimization of contrast concentration for T1-weighted spoiled gradient echo imaging.
Hernando, D; Reeder, SB; Smith, MR, 2016
)
0.43
" At the end of the treatment period, Gd was measurable in all organs sampled after single or repeated dosing and levels were dose-dependent as expected, the highest ones being found in kidneys."( Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats.
Ammerman, J; Bourrinet, P; Briffaux, JP; Corot, C; Fretellier, N; Giorgi, H, 2015
)
0.42
"The purpose of this study was to analyze quantitative and qualitative effects of estimated blood volume on venous enhancement in patients undergoing cerebral MR venography (MRV) with standard weight-based dosing of a gadolinium-based contrast agent."( Effects of Height and Blood Volume on Venous Enhancement After Gadolinium-Based Contrast Administration in MR Venography: A Paradigm Challenge and Implications for Clinical Imaging.
Dehkharghani, S; Qiu, D; Saindane, AM; Williams, TR, 2016
)
0.43
" This finding suggests that optimized dosing may affect reader confidence."( Effects of Height and Blood Volume on Venous Enhancement After Gadolinium-Based Contrast Administration in MR Venography: A Paradigm Challenge and Implications for Clinical Imaging.
Dehkharghani, S; Qiu, D; Saindane, AM; Williams, TR, 2016
)
0.43
"Standard weight-based dosing for cerebral MRV insufficiently accounts for differences in circulating blood volume."( Effects of Height and Blood Volume on Venous Enhancement After Gadolinium-Based Contrast Administration in MR Venography: A Paradigm Challenge and Implications for Clinical Imaging.
Dehkharghani, S; Qiu, D; Saindane, AM; Williams, TR, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
hexosamineAny 6-carbon amino monosaccharide with at least one alcoholic hydroxy group replaced by an amino group.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
hexoseAny six-carbon monosaccharide which in its linear form contains either an aldehyde group at position 1 (aldohexose) or a ketone group at position 2 (ketohexose).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Purinergic signaling053

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency24.54120.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency40.39970.000229.305416,493.5996AID743079; AID743080
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.00220.023723.228263.5986AID743223
activating transcription factor 6Homo sapiens (human)Potency21.87240.143427.612159.8106AID1159516
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency2.51190.01846.806014.1254AID624417
gemininHomo sapiens (human)Potency0.32640.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,688)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990350 (9.49)18.7374
1990's1006 (27.28)18.2507
2000's779 (21.12)29.6817
2010's1389 (37.66)24.3611
2020's164 (4.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 86.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index86.45 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index150.85 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (86.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials413 (9.91%)5.53%
Trials0 (0.00%)5.53%
Reviews162 (3.89%)6.00%
Reviews0 (0.00%)6.00%
Case Studies478 (11.47%)4.05%
Case Studies0 (0.00%)4.05%
Observational37 (0.89%)0.25%
Observational0 (0.00%)0.25%
Other3,078 (73.85%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]